D. E. Shaw & Co. Inc. Cuts Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

D. E. Shaw & Co. Inc. decreased its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 45.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 304,146 shares of the biopharmaceutical company's stock after selling 255,652 shares during the period. D. E. Shaw & Co. Inc. owned about 0.52% of Vanda Pharmaceuticals worth $1,457,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its position in shares of Vanda Pharmaceuticals by 16.1% during the third quarter. JPMorgan Chase & Co. now owns 160,722 shares of the biopharmaceutical company's stock worth $754,000 after purchasing an additional 22,249 shares in the last quarter. SG Americas Securities LLC boosted its position in Vanda Pharmaceuticals by 26.8% in the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock valued at $124,000 after buying an additional 5,459 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Vanda Pharmaceuticals by 4.9% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company's stock worth $3,925,000 after acquiring an additional 38,449 shares in the last quarter. Monaco Asset Management SAM increased its position in shares of Vanda Pharmaceuticals by 92.8% during the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company's stock worth $1,879,000 after acquiring an additional 188,836 shares during the period. Finally, American Century Companies Inc. raised its stake in shares of Vanda Pharmaceuticals by 2.1% in the fourth quarter. American Century Companies Inc. now owns 300,276 shares of the biopharmaceutical company's stock valued at $1,438,000 after acquiring an additional 6,079 shares in the last quarter. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on VNDA. Wall Street Zen assumed coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a "hold" rating on the stock. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th.

Insiders Place Their Bets

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock in a transaction on Wednesday, March 5th. The shares were bought at an average price of $5.02 per share, with a total value of $50,200.00. Following the purchase, the chief executive officer now directly owns 2,285,731 shares in the company, valued at $11,474,369.62. This trade represents a 0.44% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have bought 50,000 shares of company stock valued at $226,200 in the last ninety days. Insiders own 10.00% of the company's stock.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA traded up $0.05 during trading on Tuesday, hitting $4.38. 115,773 shares of the company were exchanged, compared to its average volume of 629,211. The firm's 50 day moving average price is $4.35 and its 200-day moving average price is $4.61. The stock has a market capitalization of $257.84 million, a P/E ratio of -13.67 and a beta of 0.69. Vanda Pharmaceuticals Inc. has a 12-month low of $3.81 and a 12-month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.05. The firm had revenue of $50.04 million for the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. As a group, equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.